

# Carlos A Zarate Jr

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9308699/carlos-a-zarate-jr-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

249 papers	21,317 citations	73 h-index	142 g-index
264 ext. papers	24,947 ext. citations	6.3 avg, IF	7.02 L-index

#	Paper	IF	Citations
249	A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. <i>Archives of General Psychiatry</i> , <b>2006</b> , 63, 856-64		2439
248	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , <b>2016</b> , 533, 481-4	50.4	903
247	Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. <i>Biological Psychiatry</i> , <b>2008</b> , 63, 349-52	7.9	861
246	A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. <i>Archives of General Psychiatry</i> , <b>2010</b> , 67, 793-802		702
245	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. <i>Nature Reviews Drug Discovery</i> , <b>2008</b> , 7, 426-37	64.1	633
244	Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 939-46	7.9	576
243	Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. <i>Biological Psychiatry</i> , <b>2003</b> , 53, 707-42	7.9	412
242	Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1605-11	4.6	409
241	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. <i>Pharmacological Reviews</i> , <b>2018</b> , 70, 621-660	22.5	395
240	The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 2099-107	11.9	359
239	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 150-158	11.9	311
238	An open-label trial of riluzole in patients with treatment-resistant major depression. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 171-4	11.9	289
237	Ketamine for depression: where do we go from here?. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 537-47	7.9	283
236	A double-blind, placebo-controlled study of memantine in the treatment of major depression. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 153-5	11.9	282
235	Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. <i>Biological Psychiatry</i> , <b>2004</b> , 56, 54-60	7.9	268
234	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. <i>British Journal of Psychiatry</i> , <b>2004</b> , 184, 337-45	5.4	250
233	The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. <i>Bipolar Disorders</i> , <b>2009</b> , 11 Suppl 2, 92-109	3.8	229

232	Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. <i>Neuropsychopharmacology</i> , <b>2012</b> , 37, 1526-33	8.7	225
231	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. <i>Biological Psychiatry</i> , <b>2017</b> , 81, 886-897	7.9	222
230	Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. <i>Biological Psychiatry</i> , <b>2009</b> , 65, 289-295	7.9	219
229	Ketamine and the next generation of antidepressants with a rapid onset of action. <i>Pharmacology &amp; Therapeutics</i> , <b>2009</b> , 123, 143-50	13.9	209
228	Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 1006-20	7.9	209
227	An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. <i>Biological Psychiatry</i> , <b>2005</b> , 57, 430-2	7.9	207
226	Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 331-8	7.9	187
225	A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. <i>Biological Psychiatry</i> , <b>2013</b> , 74, 257-64	7.9	178
224	The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 793-802	8.7	178
223	Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1415-22	8.7	175
222	The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. <i>Current Psychiatry Reports</i> , <b>2007</b> , 9, 467-74	9.1	175
221	Do the dissociative side effects of ketamine mediate its antidepressant effects?. <i>Journal of Affective Disorders</i> , <b>2014</b> , 159, 56-61	6.6	173
220	Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 58, 161-6	5.2	173
219	Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. <i>Bipolar Disorders</i> , <b>2007</b> , 9, 561-70	3.8	170
218	Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 2171-3	11.9	157
217	A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 551-7	1.7	152
216	Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. <i>Neuropsychobiology</i> , <b>2010</b> , 62, 50-60	4	149
215	Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. <i>Biological Psychiatry</i> , <b>2009</b> , 65, 181-4	7.9	149

214	Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. <i>Drugs</i> , <b>2012</b> , 72, 1313-33	12.1	143
213	Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1003, 273-91	6.5	143
212	Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2013</b> , 16, 301-11	5.8	141
211	Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 946-58	4.6	139
210	Glycogen Synthase Kinase-3. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 10-21	4.6	138
209	Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 555-61	7.9	135
208	Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 1155-9	5.5	135
207	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , <b>2015</b> , 6, 97-114	4.9	134
206	The neurobiology of the switch process in bipolar disorder: a review. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1488-501	4.6	133
205	The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. <i>Neuroscientist</i> , <b>2009</b> , 15, 525-39	7.6	132
204	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 596-607	4.6	128
203	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 127	8.6	127
202	Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. <i>Biological Psychiatry</i> , <b>2013</b> , 73, 1156-63	7.9	123
201	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1040-1052	15.1	123
200	Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. <i>Biological Psychiatry</i> , <b>2013</b> , 73, 1213-21	7.9	121
199	Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2014</b> , 54, 119-39	17.9	116
198	Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in $\alpha 7$ nicotinic acetylcholine receptors. <i>European Journal of Pharmacology</i> , <b>2013</b> , 698, 228-34	5.3	116
197	Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. <i>NeuroRx</i> , <b>2006</b> , 3, 22-41		111

196	The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. <i>Pharmaceuticals</i> , <b>2010</b> , 3, 19-41	5.2	108
195	Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1662-6	4.6	107
194	Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 169-71	11.9	100
193	Clinical predictors of ketamine response in treatment-resistant major depression. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e417-23	4.6	100
192	Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 1595-611	3.3	96
191	Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. <i>CNS Drugs</i> , <b>2009</b> , 23, 569-82	6.7	94
190	New targets for rapid antidepressant action. <i>Progress in Neurobiology</i> , <b>2017</b> , 152, 21-37	10.9	92
189	Convergent Mechanisms Underlying Rapid Antidepressant Action. <i>CNS Drugs</i> , <b>2018</b> , 32, 197-227	6.7	92
188	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. <i>Journal of Neural Transmission</i> , <b>2014</b> , 121, 907-24	4.3	92
187	A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1237-45	4.6	92
186	Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. <i>Human Brain Mapping</i> , <b>2013</b> , 34, 2313-29	5.9	87
185	Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 304-14	3.8	86
184	Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 582-590	7.9	82
183	Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. <i>Psychopharmacology Bulletin</i> , <b>2002</b> , 36, 35-83	0.9	80
182	Human biomarkers of rapid antidepressant effects. <i>Biological Psychiatry</i> , <b>2013</b> , 73, 1142-55	7.9	79
181	Effects of lithium on oxidative stress parameters in healthy subjects. <i>Molecular Medicine Reports</i> , <b>2012</b> , 5, 680-2	2.9	79
180	Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 5160-5169	11.5	77
179	The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2015</b> , 355, 76-85	4.7	77

178	Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder. <i>NeuroImage</i> , <b>2015</b> , 118, 1-12	7.9	77
177	The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. <i>Experimental Neurology</i> , <b>2008</b> , 211, 7-10	5.7	75
176	(S)-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 6441-6450	11.5	73
175	Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 57, 117-31	5.5	70
174	A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. <i>Bipolar Disorders</i> , <b>2008</b> , 10, 806-15	3.8	70
173	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. <i>International Journal of Neuropsychopharmacology</i> , <b>2019</b> , 22, 119-135	5.8	70
172	Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. <i>Drugs</i> , <b>2017</b> , 77, 381-401	12.1	69
171	Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. <i>JAMA Psychiatry</i> , <b>2013</b> , 70, 280-90	14.5	69
170	Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e932-8	4.6	69
169	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 383-399	11.9	67
168	Novel glutamatergic agents for major depressive disorder and bipolar disorder. <i>Pharmacology Biochemistry and Behavior</i> , <b>2012</b> , 100, 678-87	3.9	65
167	An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2012</b> , 15, 1063-72	5.8	65
166	Riluzole in psychiatry: a systematic review of the literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2008</b> , 4, 1223-34	5.5	64
165	A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. <i>Bipolar Disorders</i> , <b>2015</b> , 17, 438-43	3.8	63
164	Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. <i>Current Neuropharmacology</i> , <b>2017</b> , 15, 57-70	7.6	63
163	Existing and novel biological therapeutics in suicide prevention. <i>American Journal of Preventive Medicine</i> , <b>2014</b> , 47, S195-203	6.1	62
162	Acute D-serine treatment produces antidepressant-like effects in rodents. <i>International Journal of Neuropsychopharmacology</i> , <b>2012</b> , 15, 1135-48	5.8	61
161	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. <i>Bipolar Disorders</i> , <b>2014</b> , 16, 119-28	3.8	59

160	Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2019</b> , 59, 213-236	17.9	59
159	Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , <b>2021</b> , 278, 542-555	6.6	58
158	Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. <i>Journal of Affective Disorders</i> , <b>2017</b> , 218, 195-200	6.6	55
157	Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties. <i>Biological Psychiatry</i> , <b>2017</b> , 82, 361-369	7.9	54
156	12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 1453-9	8.7	54
155	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. <i>Psychopharmacology</i> , <b>2018</b> , 235, 3017-3030	4.7	53
154	D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. <i>Psychopharmacology</i> , <b>2015</b> , 232, 399-409	4.7	52
153	Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2018</b> , 232, 310-315	6.6	52
152	Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. <i>Bipolar Disorders</i> , <b>2012</b> , 14, 880-7	3.8	52
151	Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 819-21	5.5	52
150	Ketamine, sleep, and depression: current status and new questions. <i>Current Psychiatry Reports</i> , <b>2013</b> , 15, 394	9.1	51
149	Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 84, 113-118	5.2	51
148	Perception of facial emotion in adults with bipolar or unipolar depression and controls. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 1229-35	5.2	51
147	Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. <i>Journal of Affective Disorders</i> , <b>2013</b> , 145, 115-9	6.6	50
146	Neurobiology of bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 93-110	4.3	50
145	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , <b>2017</b> , 17, 593-609	4.3	46
144	Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 1068-1074	4.6	45
143	New therapeutic targets for mood disorders. <i>Scientific World Journal, The</i> , <b>2010</b> , 10, 713-26	2.2	45



142	A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. <i>Current Psychiatry Reports</i> , <b>2008</b> , 10, 510-9	9.1	44
141	Combination treatment in bipolar disorder: a review of controlled trials. <i>Bipolar Disorders</i> , <b>2003</b> , 5, 217-258	5.8	44
140	Glutamatergic Modulators in Depression. <i>Harvard Review of Psychiatry</i> , <b>2018</b> , 26, 307-319	4.1	43
139	Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 84-95	3.8	42
138	Bipolar disorder: candidate drug targets. <i>Mount Sinai Journal of Medicine</i> , <b>2008</b> , 75, 226-47		42
137	Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 68, 68-73	5.2	39
136	Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 297-307	8.4	39
135	Ketamine regulates the presynaptic release machinery in the hippocampus. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 892-9	5.2	39
134	Sleep architecture parameters as a putative biomarker of suicidal ideation in treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2017</b> , 208, 309-315	6.6	39
133	Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2006</b> , 3, 519-526		39
132	Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?. <i>Biological Psychiatry</i> , <b>2002</b> , 52, 921-6	7.9	39
131	Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 825-31	4.6	39
130	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. <i>Journal of Affective Disorders</i> , <b>2018</b> , 231, 51-57	6.6	38
129	Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. <i>Organic Letters</i> , <b>2017</b> , 19, 4572-4575	6.2	38
128	Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2020</b> , 263, 568-575	6.6	36
127	The influence of ketamine on drug discovery in depression. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 2033-2043	8.8	35
126	Neural correlates of suicidal ideation and its reduction in depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 18,	5.8	34
125	Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 740-747	5.8	34



124	Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2010</b> , 13, 813-32	5.8	34
123	Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. <i>NeuroImage: Clinical</i> , <b>2018</b> , 20, 92-101	5.3	33
122	Ketamine for depression: evidence, challenges and promise. <i>World Psychiatry</i> , <b>2015</b> , 14, 348-50	14.4	33
121	Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. <i>Journal of Affective Disorders</i> , <b>2017</b> , 208, 560-566	6.6	32
120	Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. <i>Brain Research Bulletin</i> , <b>2011</b> , 86, 129-33	3.9	32
119	Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	32
118	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. <i>CNS Spectrums</i> , <b>2013</b> , 18, 231-41	1.8	31
117	Characterizing the course of suicidal ideation response to ketamine. <i>Journal of Affective Disorders</i> , <b>2018</b> , 241, 86-93	6.6	30
116	Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. <i>Biological Psychiatry</i> , <b>2013</b> , 74, e23-4	7.9	29
115	NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER. <i>Translational Neuroscience</i> , <b>2013</b> , 4,	1.2	28
114	Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 254, 56-66	2.9	27
113	Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 18,	5.8	27
112	The role of dissociation in ketamine's antidepressant effects. <i>Nature Communications</i> , <b>2020</b> , 11, 6431	17.4	27
111	Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 787-800	8.7	26
110	Novel Glutamatergic Treatments for Severe Mood Disorders. <i>Current Behavioral Neuroscience Reports</i> , <b>2015</b> , 2, 198-208	1.7	26
109	Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. <i>Journal of Affective Disorders</i> , <b>2014</b> , 162, 34-8	6.6	26
108	Baseline mood-state measures as predictors of antidepressant response to scopolamine. <i>Psychiatry Research</i> , <b>2012</b> , 196, 62-7	9.9	26
107	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> , 24, 8-21	5.8	26

106	Current status of ketamine and related compounds for depression. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, 516-7	4.6	25
105	Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. <i>Handbook of Experimental Pharmacology</i> , <b>2019</b> , 253, 337-358	3.2	24
104	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 56, 91-6	5.5	24
103	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 4085-4095	15.1	24
102	Pharmacologic treatment of dimensional anxious depression: a review. <i>primary care companion for CNS disorders, The</i> , <b>2014</b> , 16,	1.2	23
101	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. <i>CNS Drugs</i> , <b>2021</b> , 35, 527-543	6.7	23
100	A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 355-358	1.7	22
99	Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 254, 67-73	2.9	22
98	Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 153-166	3.8	22
97	7T H-MRS in major depressive disorder: a Ketamine Treatment Study. <i>Neuropsychopharmacology</i> , <b>2018</b> , 43, 1908-1914	8.7	21
96	An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2016</b> , 194, 115-9	6.6	21
95	Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. <i>Psychopharmacology</i> , <b>2004</b> , 173, 227-8	4.7	21
94	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ()-hydroxynorketamine. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 12-24	4.6	21
93	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1233-1238	8.7	20
92	Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 55, 96-100	5.2	20
91	Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 2-16	3.8	20
90	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. <i>Biological Psychiatry</i> , <b>2017</b> , 81, e69-e71	7.9	20
89	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. <i>Depression and Anxiety</i> , <b>2011</b> , 28, 267-81	8.4	20

88	Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2019</b> , 22, 10-18	5.8	20
87	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 417-425	5.8	20
86	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1398-1404	8.7	20
85	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. <i>Journal of Affective Disorders</i> , <b>2015</b> , 172, 307-11	6.6	19
84	Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. <i>Psychiatry Research - Neuroimaging</i> , <b>2019</b> , 283, 64-66	2.9	19
83	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 70-76	11.9	18
82	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 280	8.6	18
81	Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2019</b> , 4, 610-618	3.4	17
80	Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation. <i>Pharmacology Biochemistry and Behavior</i> , <b>2020</b> , 189, 172856	3.9	17
79	Riluzole likely lacks antidepressant efficacy in ketamine non-responders. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 58, 197-9	5.2	17
78	Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 894-902	4.6	17
77	Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine?. <i>Biological Psychiatry</i> , <b>2010</b> , 68, 780-2	7.9	17
76	Early intervention in bipolar disorder, part I: clinical and imaging findings. <i>Microbial Biotechnology</i> , <b>2008</b> , 2, 122-35	3.3	17
75	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. <i>Pharmacological Reviews</i> , <b>2021</b> , 73, 763-791	22.5	17
74	Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion. <i>Biological Psychiatry</i> , <b>2017</b> , 82, e35-e36	7.9	16
73	Early intervention in bipolar disorder, part II: therapeutics. <i>Microbial Biotechnology</i> , <b>2008</b> , 2, 136-46	3.3	16
72	Cycling into depression from a first episode of mania: a case-comparison study. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1524-6	11.9	16
71	Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 3292-3301	15.1	16

70	Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues. <i>BMC Psychiatry</i> , <b>2019</b> , 19, 332	4.2	15
69	Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. <i>Neural Plasticity</i> , <b>2015</b> , 2015, 858251	3.3	14
68	Recognition of emotional facial expressions in anxious and nonanxious depression. <i>Comprehensive Psychiatry</i> , <b>2016</b> , 70, 1-8	7.3	13
67	Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. <i>Biological Psychiatry</i> , <b>2013</b> , 73, e37-8	7.9	13
66	GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput. <i>Bipolar Disorders</i> , <b>2016</b> , 18, 702-705	3.8	13
65	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. <i>CNS Spectrums</i> , <b>2013</b> , 18, 242-51	1.8	12
64	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , <b>2020</b> , 266, 615-620	6.6	12
63	Ketamine for Treatment-Resistant Mood Disorders. <i>Focus (American Psychiatric Publishing)</i> , <b>2019</b> , 17, 8-12	1.1	12
62	Are 24-hour motor activity patterns associated with continued rapid response to ketamine?. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 2739-2748	3.1	12
61	Ketamine Mechanism of Action: Separating the Wheat from the Chaff. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 368-369	8.7	11
60	Neurobiological biomarkers of response to ketamine. <i>Advances in Pharmacology</i> , <b>2020</b> , 89, 195-235	5.7	11
59	Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine. <i>International Journal of Neuropsychopharmacology</i> , <b>2015</b> , 18,	5.8	11
58	Can fMRI predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 130, 280-285	5.2	11
57	New Methods for Assessing Rapid Changes in Suicide Risk. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 598434	5	11
56	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 1570-1577	4.6	10
55	Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health. <i>Lancet Psychiatry</i> , <b>2016</b> , 3, 436-42	23.3	10
54	Altered interaction with environmental reinforcers in major depressive disorder: Relationship to anhedonia. <i>Behaviour Research and Therapy</i> , <b>2017</b> , 97, 170-177	5.2	8
53	Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide. <i>Biological Psychiatry</i> , <b>2015</b> , 78, 2-4	7.9	8

52	Searching for Rational Antin-methyl-D-aspartate Treatment for Depression Reply. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 1100		8
51	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. <i>Journal of Affective Disorders</i> , <b>2021</b> , 280, 136-139	6.6	8
50	Active suicidal ideation during clinical antidepressant trials. <i>Psychiatry Research</i> , <b>2017</b> , 257, 303-308	9.9	7
49	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 220-235	1.1	7
48	Development of a clinician-administered National Institutes of Health-Brief Fatigue Inventory: A measure of fatigue in the context of depressive disorders. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 68, 99-105	5.2	6
47	Biomarkers in mood disorders research: developing new and improved therapeutics. <i>Revista De Psiquiatria Clinica</i> , <b>2014</b> , 41, 131-134	0.8	6
46	Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses.. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 54, 100-115	1.2	6
45	Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2020</b> , 5, 354-363	3.4	6
44	Disentangling the association of depression on the anti-fatigue effects of ketamine. <i>Journal of Affective Disorders</i> , <b>2019</b> , 244, 42-45	6.6	6
43	Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 61, 40-5	5.2	5
42	Bipolar disorder: a neurobiological synthesis. <i>Current Topics in Behavioral Neurosciences</i> , <b>2011</b> , 5, 331-40	3.4	5
41	Mapping anticipatory anhedonia: an fMRI study. <i>Brain Imaging and Behavior</i> , <b>2019</b> , 13, 1624-1634	4.1	4
40	Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 200	8.6	4
39	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. <i>Neurotoxicology and Teratology</i> , <b>2021</b> , 87, 106993	3.9	4
38	Ketamine treatment for depression: a review.. <i>Discover Mental Health</i> , <b>2022</b> , 2, 9		4
37	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 243-246	1.7	3
36	Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling. <i>International Journal of Neuropsychopharmacology</i> , <b>2006</b> , 9, 263-6	5.8	3
35	Ketamine for Bipolar Depression: A Systematic Review. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> , 24, 535-541	5.8	3

34	Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 335	8.6	3
33	Potential novel therapeutics for bipolar disorders. <i>Current Topics in Behavioral Neurosciences</i> , <b>2011</b> , 5, 303-29	3.4	2
32	Molecular mechanisms of bipolar disorder. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2005</b> , 2, 435-445		2
31	Not So Fast: Recent Successes and Failures in Treating Depression. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	2
30	Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , <b>2021</b> , 279, 239-249	6.6	2
29	Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine. <i>Suicide and Life-Threatening Behavior</i> , <b>2021</b> , 51, 27-35	3.9	2
28	Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?. <i>Journal of Affective Disorders</i> , <b>2021</b> , 282, 258-260	6.6	2
27	Evaluation of the safety, tolerability and pharmacokinetic profiles of TP0473292 (TS-161), a prodrug of a novel orthosteric mGlu2/3 receptor antagonist TP0178894, in healthy subjects and its antidepressant-like effects in rodents. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> ,	5.8	2
26	Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 86, 55-57	5.2	1
25	Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2006</b> , 4, 181-190		1
24	The relationship between the HDRS insomnia items and polysomnographic (PSG) measures in individuals with treatment-resistant depression.. <i>Journal of Psychiatric Research</i> , <b>2022</b> , 148, 27-33	5.2	1
23	A wake-up call - revealing the oversight of sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants		1
22	Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , <b>2021</b> , 66, 537-539	4.8	1
21	Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 673159	5	1
20	Overview of ketamine for major depression: efficacy and effectiveness <b>2021</b> , 117-129		1
19	A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants. <i>Progress in Neurobiology</i> , <b>2021</b> , 206, 102140	10.9	1
18	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 179	8.6	1
17	Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".. <i>CNS Drugs</i> , <b>2022</b> , 36, 205	6.7	0



16	The mental health impact of contact with COVID-19 patients on healthcare workers in the United States.. <i>Psychiatry Research</i> , <b>2021</b> , 308, 114359	9.9	o
15	Glutamate modulators and beyond: A neuroscience revolution in the making. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 54, 72-72	1.2	o
14	A Predictive Coding Framework for Understanding Major Depression.. <i>Frontiers in Human Neuroscience</i> , <b>2022</b> , 16, 787495	3.3	o
13	Sex-dependent metabolism of ketamine and ()-hydroxynorketamine in mice and humans.. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 2698811211064922	4.6	o
12	Effects of stress on endophenotypes of suicide across species: A role for ketamine in risk mitigation. <i>Neurobiology of Stress</i> , <b>2022</b> , 100450	7.6	o
11	Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2017</b> , 2, 549-551	3.4	
10	Novel Therapeutic Strategies for Bipolar Disorder <b>2010</b> , 395-411		
9	The acute treatment of bipolar depression: Historically relevant and recent controlled trials. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2006</b> , 4, 151-158		
8	Ketamine: a new chapter in antidepressant development. <i>Revista Brasileira De Psiquiatria</i> , <b>2020</b> , 42, 581-582		
7	Potential Novel Treatments in Bipolar Depression. <i>Milestones in Drug Therapy</i> , <b>2016</b> , 259-285		
6	Potential novel treatments for bipolar depression <b>2009</b> , 191-209		
5	Novel Therapeutic Approaches for Treating Bipolar Disorder423-445		
4	Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior <b>2014</b> , 209-221		
3	Reply to: "Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightnessare not the same - A comment on Acevedo-Díaz et al." (Jpsychiatres-D-21-00121). <i>Journal of Psychiatric Research</i> , <b>2021</b> , 137, 403-410	5.2	
2	The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC <b>2019</b> , 1-8		
1	Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.. <i>Current Topics in Behavioral Neurosciences</i> , <b>2022</b> , 1	3.4	